Press Release

The global Alpha 1 Antitrypsin Deficiency Treatment market will reach 2560 million US$ by the end of 2025, growing at a CAGR of 10.1% during 2018-2025.

Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis, and hepatocellular carcinoma.

The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called ‘additional therapies’). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold.

Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option.
Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT).

The global Alpha 1 Antitrypsin Deficiency Treatment market is valued at XX million US$ and will reach 2560 million US$ by the end of 2025, growing at a CAGR of 10.1% during 2018-2025.

Global Alpha 1 Antitrypsin Deficiency Treatment Market Professional Survey Report 2018 is a professional and in-depth study and available exclusively through Trusted Business Insights. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets in this 124 pages report.

This market report provides in-depth analytics of the Alpha 1 Antitrypsin Deficiency Treatment industry including definition, classification, application and industry chain structure. The report focuses on global major leading industry players with information such as company profiles, product picture and specifications, sales, market share, and contact information.

Request for a Sample PDF of Alpha 1 Antitrypsin Deficiency Treatment research report

Alpha 1 Antitrypsin Deficiency Treatment market report includes an in-depth analysis of the competitive landscape of this business vertical, constituting companies like:

Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Shire
LFB Biomedicaments
Abeona Therapeutics
Biogen
Applied Genetic Technologies
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Curaxys
ProMetic Life Sciences

Products Segmentation, this report displays the production, revenue, price, market share, and growth rate of each type as below:

Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy

By Industrial Application, the market can be split into:

Hospitals
Specialty Clinics
Pharmacies

Market Segment by Regions includes:

  • North America (the USA, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, and Italy)
  • Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
  • South America
  • Middle East and Africa.

Browse contents of Global Alpha 1 Antitrypsin Deficiency Treatment Market Professional Survey Report 2018

Contacts

Trusted Business Insights
Jessica Wang
Media & Marketing Executive
[email protected]
US: +1 646 568 9797
UK: +44 330 808 0580